LifeStance Health Group (NASDAQ:LFST) Upgraded by The Goldman Sachs Group to Buy Rating

LifeStance Health Group (NASDAQ:LFST) was upgraded by research analysts at The Goldman Sachs Group from a “neutral” rating to a “buy” rating in a note issued to investors on Monday, Marketbeat.com reports. The firm currently has a $10.00 price objective on the stock. The Goldman Sachs Group’s price target indicates a potential upside of 39.47% from the company’s current price.

Separately, Barclays boosted their target price on shares of LifeStance Health Group from $6.00 to $7.00 and gave the company an “underweight” rating in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, LifeStance Health Group currently has an average rating of “Hold” and an average price target of $8.70.

LifeStance Health Group Price Performance

NASDAQ:LFST opened at $7.17 on Monday. The stock has a 50 day moving average of $7.17 and a two-hundred day moving average of $6.33. LifeStance Health Group has a 12 month low of $4.64 and a 12 month high of $9.20. The firm has a market cap of $2.74 billion, a P/E ratio of -27.58 and a beta of 1.28. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.19.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.05. LifeStance Health Group had a negative return on equity of 6.66% and a negative net margin of 7.90%. The firm had revenue of $312.70 million during the quarter, compared to the consensus estimate of $302.25 million. During the same period in the prior year, the company earned ($0.17) EPS. The firm’s revenue was up 18.9% compared to the same quarter last year. On average, analysts expect that LifeStance Health Group will post -0.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In other LifeStance Health Group news, Director Robert Bessler sold 75,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $7.54, for a total value of $565,500.00. Following the sale, the director now owns 1,424,447 shares of the company’s stock, valued at $10,740,330.38. The trade was a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 6.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its position in shares of LifeStance Health Group by 3.5% during the second quarter. Bank of New York Mellon Corp now owns 451,102 shares of the company’s stock worth $2,215,000 after acquiring an additional 15,309 shares during the period. CIBC Asset Management Inc purchased a new stake in LifeStance Health Group during the 2nd quarter worth about $53,000. Rhumbline Advisers raised its position in LifeStance Health Group by 17.6% in the 2nd quarter. Rhumbline Advisers now owns 182,131 shares of the company’s stock valued at $894,000 after purchasing an additional 27,280 shares in the last quarter. TD Asset Management Inc purchased a new position in shares of LifeStance Health Group in the 2nd quarter valued at about $623,000. Finally, Victory Capital Management Inc. grew its position in shares of LifeStance Health Group by 27.0% during the second quarter. Victory Capital Management Inc. now owns 14,407 shares of the company’s stock worth $71,000 after buying an additional 3,063 shares in the last quarter. Hedge funds and other institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.